logo-loader

Robinson cuts profit expectations as weaker UK demand weighs

Published: 02:54 23 Oct 2026 EDT

Robinson PLC - Robinson cuts profit expectations as weaker UK demand weighs

Robinson PLC (AIM:RBN) has cut its profit expectations for 2026 after weaker-than-anticipated demand in its UK paperboard and plastics businesses.

The packaging manufacturer now expects underlying operating profit of between £1.2 million and £1.6 million for the year ending 31 December.

Revenue is still expected to rise 6% to around £59 million, although sales volumes are forecast to be 1% below 2025 levels.

The company said demand had been softer than expected since September, particularly across its Paperbox and UK Plastics operations.

Paperbox sales expectations have been reduced by £1 million because of a lack of new business and lower orders from key customers.

UK Plastics sales expectations have been cut by £1.3 million following lower volumes from one customer, a filling-line breakdown at another and weaker seasonal demand during warmer weather.

Higher energy costs linked to the conflict in the Middle East have also put additional pressure on profitability.

Robinson said Denmark continued to trade in line with expectations, while conditions in Poland remained challenging.

The group is reviewing cost-saving opportunities in response to the weaker demand and is continuing to strengthen its sales operations.

Excluding any benefit from those measures, Robinson expects profitability in 2027 to be broadly in line with 2026.

The company said it remains committed to achieving an underlying operating margin of between 6% and 8% over time.

Robinson has also generated £1.5 million from surplus property sales so far this year.

One further property sale has been delayed until the second quarter of 2027, although another disposal is expected to complete within the next three months.

Reported pre-tax profit for 2026 is expected to benefit from the property disposals.

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

2 hours, 24 minutes ago